Related Experiment Video

Updated: Sep 28, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

EGFR Inhibitor CL-387785 Suppresses the Progression of Lung Adenocarcinoma

Yong Cai1, Zhaoying Sheng1, Zhiyi Dong2

  • 1Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.

Current Molecular Pharmacology
|March 30, 2022
PubMed
Abstract

Insights

The irreversible EGFR inhibitor CL-387785 reduces non-small cell lung cancer cell invasion and metastasis. This compound also enhances radiotherapy sensitization, offering potential therapeutic benefits.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths.
  • Epidermal Growth Factor Receptor (EGFR) is a key target in NSCLC treatment.
  • Novel therapeutic strategies are needed to overcome resistance and improve outcomes.

Purpose of the Study:

  • To investigate the effects of the irreversible EGFR inhibitor CL-387785 on NSCLC cell invasion, metastasis, and radiosensitivity.
  • To evaluate the potential of CL-387785 as an adjunct therapy in NSCLC.

Main Methods:

  • MTT assay for proliferation inhibition.
  • Flow cytometry for apoptosis analysis.
  • Transwell and wound healing assays for invasion and migration.
  • Clonogenic survival assay for radiosensitization under X-ray irradiation.

Main Results:

  • CL-387785 demonstrated dose- and time-dependent inhibition of H1975 cell proliferation.
  • The compound promoted apoptosis and reduced cell migration and invasion.
  • CL-387785 significantly enhanced radiosensitivity, with sensitization ratios (SER) ranging from 1.17 to 3.64 at tested concentrations.

Conclusions:

  • Irreversible EGFR inhibitor CL-387785 effectively suppresses invasion and metastasis in NSCLC cells.
  • CL-387785 exhibits significant radiosensitizing properties, indicating its potential as a therapeutic agent in NSCLC treatment.
Keywords:
EGFR inhibitoradenocarcinomachemoradiotherapyinvasion and metastasisnon-small cell lung cancerradiotherapy sensitization

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
236
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K